Solventum Corporation (SOLV)
$
72.66
-0.23 (-0.32%)
Key metrics
Financial statements
Free cash flow per share
0.8443
Market cap
12.6 Billion
Price to sales ratio
1.5020
Debt to equity
2.1440
Current ratio
1.2244
Income quality
1.5421
Average inventory
914 Million
ROE
0.1164
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Solventum Corporation, a healthcare company incorporated in 2023 and based in Saint Paul, Minnesota, is focused on developing, manufacturing, and commercializing a diverse range of solutions to meet critical customer and patient needs. The company operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment offers an array of products, including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes. Meanwhile, the Dental Solutions segment provides an extensive suite of dental and orthodontic products such as brackets, aligners, restorative cements, and bonding agents. Health Information Systems is dedicated to delivering software solutions like computer-assisted physician documentation, direct-to-bill and coding automation, classification methodologies, speech recognition, and data visualization platforms. In addition, the Purification and Filtration segment features advanced purification and filtration technologies encompassing filters, purifiers, cartridges, and membranes. The company's operating expenses amount to $3,557,000,000.00 encompassing various operational costs incurred. With reported revenue of $8,254,000,000.00 the company reflects a strong market presence. Moreover, the operating income ratio stands at 0.13 indicating the company's operational profitability margin, while the weighted average number of shares outstanding is 173,200,000.00 highlighting the company's shareholder base. The company's stock is identified with the symbol 'SOLV' in the market. Investors will find the stock reasonably priced at $74.07 appealing to a broad range of market participants. With an average trading volume of 977,192.00 the stock indicates moderate liquidity, which can facilitate trading activities for shareholders. Solventum Corporation boasts a mid-range market capitalization of $12,598,357,548.00 establishing it as a steady performer. As a key player in the Medical - Care Facilities industry, the company significantly contributes to the overall market landscape, driving innovation and growth within the healthcare sector, wherein it belongs to the Healthcare sector. This combination of solid financial performance and strategic positioning underscores Solventum Corporation’s potential as a valuable investment opportunity within the dynamic healthcare market.
Investing in Solventum Corporation (SOLV) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B, with a Bullish outlook. Always conduct your own research before investing.
Analysts predict Solventum Corporation stock to fluctuate between $60.70 (low) and $85.92 (high) in the next 365 days, reflecting market expectations and potential volatility.
As of 2025-08-29, Solventum Corporation's market cap is $12,598,357,548, based on 173,387,800 outstanding shares.
Compared to Meta Platforms, Inc. Class A Common Stock, Solventum Corporation has a Lower Market-Cap, indicating a difference in performance.
To buy Solventum Corporation (SOLV) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SOLV. Place an order (Market, Limit, etc.).
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Revenue: $8,254,000,000 | EPS: $2.77 | Growth: -64.44%.
Visit https://www.solventum.com/investor-relations for detailed financial reports.
You can explore historical data from here
All-time high: $85.92 (2025-02-26) | All-time low: $47.16 (2024-07-16).
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
prnewswire.com
ST. PAUL, Minn. , Aug. 22, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV) announced today that it has commenced offers (each, a "Tender Offer" and, collectively, the "Tender Offers") to purchase its outstanding notes of the series listed in the table below (collectively, the "Notes") for up to $1.75 billion aggregate purchase price in cash (the "Aggregate Cap").
prnewswire.com
ST. PAUL, Minn. , Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV) (the "Company" or "Solventum") today announced the pricing of the previously announced secondary offering (the "Offering") of 8,800,000 shares of its common stock, which is expected to result in gross proceeds of approximately $648 million to 3M Company (the "Selling Shareholder").
prnewswire.com
ST. PAUL, Minn. , Aug. 13, 2025 /PRNewswire/ -- Solventum Corporation (NYSE: SOLV, "Company" or "Solventum") today announced the launch of a secondary offering (the "Offering") of 8,800,000 shares of its common stock, par value $0.01 per share, by 3M Company (the "Selling Shareholder").
zacks.com
SOLV jumps 5% as Q2 earnings and revenues beat estimates; EPS outlook raised on broad-based segment growth.
seekingalpha.com
Solventum Corporation (NYSE:SOLV ) Q2 2025 Earnings Conference Call August 7, 2025 4:30 PM ET Company Participants Amy Wakeham - Senior Vice President of Investor Relations & External Finance Communications Bryan C. Hanson - CEO & Director Wayde D.
zacks.com
Solventum (SOLV) came out with quarterly earnings of $1.69 per share, beating the Zacks Consensus Estimate of $1.45 per share. This compares to earnings of $1.56 per share a year ago.
reuters.com
Medical device maker Solventum raised full-year adjusted profit forecast on Thursday, driven by strong sales of its wound care and surgical sterilization products alongside lower expenses.
zacks.com
SOLV's Q2 earnings are likely to test whether solid segment growth can offset tariff and ERP-related pressures.
seekingalpha.com
Solventum's $4.1B sale of its purification business to Thermo Fisher significantly reduces debt and enhances financial stability, improving long-term prospects. Despite near-term earnings pressure from higher costs and separation expenses, organic growth has accelerated and future guidance has improved. Valuation has become compelling after the share price pullback, with sustainable EPS estimated at $5.50-$6.00 and leverage much lower post-divestment.
See all news